Is Veeva Systems profitable in 2026?

Yes. Veeva reported FY2026 (ended Jan 31, 2026) net income of $908 million on total revenue of about $3.2 billion, up roughly 16% year over year, with Q1 FY2027 operating cash flow of $1.13 billion, confirming strong, sustained profitability.

Could AI replace Veeva Systems?

Unlikely soon. Veeva is building AI agents (Falcon, Vault CRM Bot) into its own regulated GxP and 21 CFR Part 11 validated workflows, using Anthropic Claude via AWS Bedrock as an ingredient. Its moat is compliance validation and 1,500+ customer lock-in, not raw model capability, which AI alone cannot replicate quickly.

Who is Veeva Systems' biggest competitor?

Salesforce, its former CRM hosting partner, now ships a direct rival, Life Sciences Cloud (Agentforce Life Sciences), built on licensed IQVIA OCE data, generally available since around September/October 2025, during a forced migration window running through 2030 for legacy Veeva CRM customers.

Is joining Veeva Systems as an employee safe right now?

Signals suggest yes: headcount grew to 7,928 employees as of January 31, 2026, up 8.7% year over year, alongside 16% revenue growth and $908 million FY2026 net income. Active job postings rose 19% year over year in 2025 per Revelio Labs data, indicating continued hiring rather than contraction.

Who owns Veeva Systems?

Veeva Systems is an independent public company trading on the NYSE under ticker VEEV since its October 2013 IPO at $20 a share. It has no parent company and became the first publicly traded firm to convert to a Delaware Public Benefit Corporation in February 2021, with 99% shareholder approval.

Is Veeva Systems losing customers to Salesforce's new life sciences product?

As of mid 2026 there is no public evidence of top pharma accounts switching to Salesforce Life Sciences Cloud; Veeva's growth remained at 16% YoY in Q1 FY2027 (quarter ended April 30, 2026). Legacy Salesforce-hosted Veeva CRM customers have until 2030 to migrate, keeping the outcome undecided.

Medical technology and health companies · United States

Veeva Systems

veeva.com ↗

Cloud software running clinical, regulatory, and sales workflows for drug makers.

Defensible for now

Assessed 22 July 2026 · Evidence as of 22 July 2026

Real protection, with named pressure against it.

On the recordSince 22 July 2026 · Checkable from November 2026 · Every call on the record Checkpoint: Falcon AI agents general availability and early adoption results

The call

Veeva keeps growing 16% a year on regulatory lock-in while Salesforce tests whether the 2030 migration window is a real opening or just a shipped product with no customers yet.

Veeva sells record-keeping and customer-management software to pharmaceutical and life-sciences companies. The software is hard to replace because it is built to follow strict government rules (21 CFR Part 11) and switching away requires expensive validation work that takes years. However, Salesforce, which used to be Veeva's hosting partner, has now built its own competing product and is selling it directly to the same customers. The real question is whether Salesforce can actually win customers away during the next three to four years when drug companies are forced to upgrade their systems anyway, or whether Veeva's locked-in customers stay put.

Why

AI pressure: Anthropic Claude (via Veeva's own Falcon agents on AWS Bedrock). Veeva builds Claude into its own agents rather than getting replaced by them, so AI is feeding its product, not eating it yet. Could AI do the core job? Unlikely.

Bigger players: Salesforce (Life Sciences Cloud plus Agentforce, ex-hosting partner). Salesforce shipped a direct CRM rival timed to a 2030 deadline when pharma must migrate off Veeva's old hosting setup. Could a giant copy it? No, they are blocked.

What protects it. Regulated workflows (21 CFR Part 11, GxP validation) glue 1,500+ customers in for years once installed.

What would change this call

Any top-20 pharma announces switching commercial CRM to Salesforce Life Sciences Cloud or IQVIA OCE by 2027. Would show Veeva's regulated-workflow lock-in is breakable during the 2030 migration window.
Veeva's Falcon AI product adoption metrics disclosed after November 2026 GA launch. Weak uptake would suggest Veeva's AI layer is lagging Salesforce's Agentforce push.

Key numbers

FY2026 revenue $3.2B, up 16% YoY (2026-01-31)
FY2026 net income $908M (2026-01-31)
Q1 FY2027 operating cash flow $1.13B (2026-04-30)

Named risks

Salesforce/IQVIA CRM rival winning top-20 pharma accounts during 2027-2030 migration window. Severity: high
Falcon agentic platform (GA Nov 2026) failing to gain early-adopter traction, denting FY2028 guidance. Severity: medium
Investor skepticism over AI monetization already visible: stock fell despite Q1 FY2027 beat on June 3, 2026. Severity: medium
Dependence on Anthropic Claude via AWS Bedrock for core AI agent features creates third-party model reliance. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Salesforce	contesting	Shipped Life Sciences Cloud GA around Sept/Oct 2025 during Veeva's forced 2030 CRM migration window
IQVIA	contesting	Settled 8-year lawsuit Aug 2025, formed data partnership while its OCE CRM still competes through 2029
Oracle	losing to	Siebel Pharma CRM/Oracle CX require more configuration to match Veeva compliance parity, per Jan 2026 industry comparison

Questions people ask

Is Veeva Systems profitable in 2026?: Yes. Veeva reported FY2026 (ended Jan 31, 2026) net income of $908 million on total revenue of about $3.2 billion, up roughly 16% year over year, with Q1 FY2027 operating cash flow of $1.13 billion, confirming strong, sustained profitability.
Could AI replace Veeva Systems?: Unlikely soon. Veeva is building AI agents (Falcon, Vault CRM Bot) into its own regulated GxP and 21 CFR Part 11 validated workflows, using Anthropic Claude via AWS Bedrock as an ingredient. Its moat is compliance validation and 1,500+ customer lock-in, not raw model capability, which AI alone cannot replicate quickly.
Who is Veeva Systems' biggest competitor?: Salesforce, its former CRM hosting partner, now ships a direct rival, Life Sciences Cloud (Agentforce Life Sciences), built on licensed IQVIA OCE data, generally available since around September/October 2025, during a forced migration window running through 2030 for legacy Veeva CRM customers.
Is joining Veeva Systems as an employee safe right now?: Signals suggest yes: headcount grew to 7,928 employees as of January 31, 2026, up 8.7% year over year, alongside 16% revenue growth and $908 million FY2026 net income. Active job postings rose 19% year over year in 2025 per Revelio Labs data, indicating continued hiring rather than contraction.
Who owns Veeva Systems?: Veeva Systems is an independent public company trading on the NYSE under ticker VEEV since its October 2013 IPO at $20 a share. It has no parent company and became the first publicly traded firm to convert to a Delaware Public Benefit Corporation in February 2021, with 99% shareholder approval.
Is Veeva Systems losing customers to Salesforce's new life sciences product?: As of mid 2026 there is no public evidence of top pharma accounts switching to Salesforce Life Sciences Cloud; Veeva's growth remained at 16% YoY in Q1 FY2027 (quarter ended April 30, 2026). Legacy Salesforce-hosted Veeva CRM customers have until 2030 to migrate, keeping the outcome undecided.

Timeline

2026-06-23Veeva acquires Copli, launches Falcon MLR content-review AI product
2026-06-16Veeva reports Q1 FY2027 revenue $882.9M, up 16% YoY, raises FY2027 guidance
2026-06-03VEEV stock falls despite beating Q1 FY2027 earnings estimates
2026-05-27Veeva announces Falcon, an agentic platform for drug development, GA planned Nov 2026
2026-03-01Veeva acquires Ostro, an AI-agent patient/HCP engagement platform, for about $100 million
2025-12-03Veeva AI Agents reach general availability for Vault CRM and PromoMats, free through 2030
2025-10-01Salesforce Life Sciences Cloud (Agentforce Life Sciences) reaches general availability
2025-09-01Veeva completes migration of customers off Salesforce-hosted CRM to its own Vault CRM
2025-08-01IQVIA and Veeva settle eight-year antitrust/trade-secret lawsuit, form new data partnership
2021-01-12Veeva becomes first public company to convert to a Delaware Public Benefit Corporation

Revision history

22 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Abridge Seegene Olympus Corporation

More in Medical technology and health companies →

Sources

Veeva Systems (VEEV) Revenue 2011-2026 (2026-07-08)
Veeva Announces Fiscal 2027 First Quarter Results (2026-06-16)
Veeva Systems (2026-06-16)
8-K (2013-10-21)
Veeva Becomes First Public Company to Convert to a Public Benefit Corporation (2021-01-12)
gurufocus.com (2026-07-22)
Veeva Systems (VEEV) Number of Employees 2014-2026 (2026-06-28)
Veeva Systems Number of Employees 2026 (2026-06-29)
Navigating the Salesforce-Veeva Split for Life Sciences (2025-10-09)
Veeva Announces AI in Vault CRM (2025-05-16)
Veeva AI Agents Now Available (2026-02-10)
Veeva Announces Falcon (2026-05-27)